Motley Fool |
Will This Trend Cost Biotech Stock Investors Lots of Money?
Motley Fool If real-world results don't match up to clinical study results, then the new pricing model will cause Regeneron, Sanofi, and Amgen to make less money on their cholesterol drugs than they would have under a traditional pricing model. The companies are ... |
October 30, 2016 at 04:06PM | money - Google News
Will This Trend Cost Biotech Stock Investors Lots of Money? - Motley Fool
money - Google News
money - Google News | October 30, 2016 at 04:06PM | Will This Trend Cost Biotech Stock Investors Lots of Money? - Motley Fool
Nenhum comentário:
Postar um comentário